Downloads
Abstract
Aims: To evaluate some factors affecting the survival of non-small cell lung cancer patients with brain metastasis treated at hospital K.
Population: Patients were diagnosed non-small cell lung cancer metastatic brain, treated by Paclitaxel- Carboplatin regimen combined with cerebral radiotherapy at K hospital from 01/2016-6/2018.
Methods: Case series study
Results: The median progress free survival in the group with under 3 brain metastases was 7.8 months that was those with ≥ 3 brain metastasis as 6.2 months (p=0.03). In the group, median PFS of patients with one brain metastasis had was 8.5 months, after 6 months was 79.2%, significantly higher than that of the group with external brain metastases with 6.5 months, 36.4 months, respectively (p=0.02). The higher risk ratio and lower PFS were in the group of patients <60 years old, ≥1 metastatic organs, ≥2 brain metastases; especially statistically significant when being male (p <0.05).
Conclusion: Factors associated with higher risk rate and lower survival time when patients <60 years old, ≥1 metastatic organs, ≥2 brain metastases (statistically significant in OS). Especially when male, is statistically significant in both PFS and OS. The low cost method is suitable for general conditions in Vietnam.
Key words: Non-small cell lung cancer, brain metastase, prognosis
References
Dela Cruz CS, Tanoue LT, Matthay RA (2011). Lung cancer: epidemiology and prevention. Clin Chest Med, 32(4), 605-644.
International Agency for Research on Cancer (2012). Estimated Cancer Incidence, Mortality and Prevalence Worldwide.
Bùi Diệu, Nguyễn Bá Đức và Trần Văn Thuấn (2010). Tình hình mắc ung thư tại Việt Nam 2004-2008 qua số liệu của 6 vùng. Tạp chí Ung thư học Việt Nam, 1/2010, 75-77.
W. D. Travis, E. Brambilla, A. G. Nicholson et al (2015). The 2015 World Health Organization
Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J Thorac Oncol, 10(9), 1243-1260.
National Comprenhisive Cancer Network (2013). Central nervous system cancers. Clinical practice guidelines in oncology, V.2, 2013,
National Comprehensive Cancer Network (2014). Non Small Cell Lung Cancer. Clinical practice guidelines in oncology.
Lê Thị Huyền Sâm (2012). Đánh giá kết quả điều trị ung thư phổi không tế bào nhỏ giai đoạn IIIB-IV bằng phác đồ Paclitaxel-Carboplatin tại Hải Phòng, Đại học Y Hà Nội, Luận văn thạc sĩ.
Trương Thị Kiều Oanh (2017). Đánh giá đáp ứng hóa chất phác đồ Paclitaxe - Carboplatin bước 1 ở bệnh nhân ung thư phổi không tế bào nhỏ giai đoạn IIIB-IV trên 60 tuổi, Luận văn thạc sĩ, Đại học Y Hà Nội.
Stathopoulos G.P, Veslemes M, Georgatou N et al (2004). Front-line paclitaxel–vinorelbine versus paclitaxel–carboplatin in patients with advanced non-small-cell lung cancer:a randomized phase III trial. Annals of oncology, 15, 1048-1055.
T. S. Mok, Y. L. Wu, S. Thongprasert et al (2009). Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med, 361 (10), 947-957.
Zhou C, Chen G, Liu X et al (2013). BEYOND: A Randomized, Double-blind, Placebo- controlled, Multicentre Phase III Study of First- line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients with Advanced or Recurrent on-squamous Non-small-cell Lung Cancer. Thorac Oncol, 8(Suppl 2), Abstract MO06.13
Nguyễn Thị Thái Hòa, Nguyễn Thị Thanh Huyền, Mai Thanh Huyền và cộng sự (2018). Đánh giá kết quả điều trị thuốc ức chế Tyrosine kinase ung thư phổi không tế bào nhỏ di căn não. Tạp chí Y học Việt Nam, Tập 464, 322-326.
C. Zhou, Y. L. Wu, G. Chen et al (2015). BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol, 33(19), 2197-2204.
H. Harada, H. Asakura, H. Ogawa et al (2016). Prognostic factors in patients with brain metastasis from non-small cell lung cancer treated with whole-brain radiotherapy. J Cancer Res Ther, 12(1), 267-270.
| Published | 19-02-2025 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | No. 55 (2019) | |
| Section | Original article | |
| DOI | ||
| Keywords | UTP không tế bào nhỏ, di căn não, tiên lượng Non-small cell lung cancer, brain metastase, prognosis |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2019 Journal of Clinical Medicine Hue Central Hospital